Member Info for tuscany1

Https://www.youtube.com/watch?v=7z_YteRS-5E

Yes 505b-2 seems like a big plus.

Https://pharmaphorum.com/oncology/targeting-blood-cancers-high-unmet-need..

Interesting background on AML cancers etc underscoring the high unmet need in this area .

Indeed .

https://www.fiercepharma.com/pharma/site-irregularities-bristol-myers-delays-key-cobenfy-readout-alzheimers-psychosis?

Https://financialpost.com/pmn/business-pmn/top-paid-uk-oil-ceo-fights-forgery-claims-as-he-chases-north-sea-deal

Https://www.youtube.com/watch?v=ICszRwC3o04

Daphne Zohar interview ..

Https://www.marketwatch.com/story/why-biotech-and-drug-stocks-are-on-the-mend-even-though-the-rest-of-the-market-is-hurting-739d7317?mod=mw_latestnews

You have to laugh ...

Networking Session: From 8:30pm onwards at Muddy Murphys, Happy Hour prices are available all night (and at any time) upon presentation of a SEAPEX membership card.

The thing is there's no guarantee that Celea will get the funding for a phase 3 .

This is why probably Jamie Ward describes PRTC as a lottery ticket ..

Just saying .

Indeed Dallo .

Well I bought my last 10k on that news .

So in the end given that the structure of PRTC has been much simplified we will find out if Mr Market likes the value proposition here .

Looks like a really smart move ...leaving the rump of Puretech ripe for a Takeover bid.

Seascape is a very instructive example of how much the Management Team can make to a company .

You dont see this very often and when you find it you should hold it close .

They never overpromise and they just keep delivering .

Seaport just starting a new trial for Depression

https://pharmatimes.com/news/seaport-therapeutics-begins-phase-2b-trial-of-glyphallo-for-major-depression/

But could this be an early treatment for Alzheimers too ?

Just been doing some research which suggests that's a possibility too .

https://www.youtube.com/watch?v=kFJOLXoAR34

https://www.regenbrain.org/new-approach

So that really would be a blockbuster too after Cobenfy .

All very interesting ..am starting to feel cheerful again about PRTC.!

Where is their new broker UBS- appointed 3 months ago - in all this .

Is their some special reason they havent put out a note so far .

Are they waiting for results end April ?

Https://www.youtube.com/watch?v=aRl_-PIydWQ

Here it is ...

Well you know the answer based on the last published accounts .

Its basically 50/50.

Even yesterday you could sell in volume if you wanted to,

I have 50k at average 166p.

I can wait for the market to catch up..the Seaport holding and specifically their Glyph technology could be worth anything .

Would be nice if their new broker UBS -appointed at the start of the year- could release an updated note

Tipped by Simon Thompson today in IC.

One of his eight bargain shares of 2025.

Target price at least 60p

The Board has declared a fourth interim dividend for Q4 2024 of 16p per share (Q4 2023: 16p per share).

Dividends remain an essential component of total shareholder return and GSK recognises the importance of dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60 per cent pay-out ratio through the investment cycle. Consistent with this, GSK has declared a dividend of 16p for Q4 2024 and 61p per share for full year 2024. The expected dividend for 2025 is 64p per share. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment strategy for growth alongside the sustainability of the dividend.

Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 8 April 2025. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. The ex-dividend and record dates will be 21 February 2025 with a payment date of 10 April 2025.

Can someone tell me what is the exercise price of the new options ?